Medincell Sa Stock Today
| MDCLF Stock | USD 6.98 7.02 50.14% |
Performance0 of 100
| Odds Of DistressLess than 24
|
MedinCell is trading at 6.98 as of the 23rd of December 2024. This is a 50.14% down since the beginning of the trading day. The stock's lowest day price was 6.98. MedinCell has about a 24 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 23rd of November 2024 and ending today, the 23rd of December 2024. Click here to learn more.
It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. Its product candidates in formulation research comprise subcutaneous injections, such as mdc-WWM for contraception mdc-ANG for CNS related treatments mdc-ELK for depression and mdc-GRT for use in organ transplant, as well as perineural injections, including mdc-CMV for anesthesia and pain, and mdc-NVA for pain. The company has 25.22 M outstanding shares. More on MedinCell SA
MedinCell Pink Sheet Highlights
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
MedinCell SA [MDCLF] is a Pink Sheet which is traded between brokers as part of OTC trading. The company currently falls under 'Small-Cap' category with a current market capitalization of 244.65 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate MedinCell's market, we take the total number of its shares issued and multiply it by MedinCell's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. MedinCell SA classifies itself under Healthcare sector and is part of Biotechnology industry. The entity has 25.22 M outstanding shares.
MedinCell SA has accumulated about 34.39 M in cash with (21.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.38.
Check MedinCell Probability Of Bankruptcy
Ownership AllocationMedinCell SA maintains a total of 25.22 Million outstanding shares. MedinCell SA holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check MedinCell Ownership Details
MedinCell Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in MedinCell without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Analyst Advice Now
Analyst AdviceAnalyst recommendations and target price estimates broken down by several categories |
| All Next | Launch Module |
MedinCell Corporate Management
| Joel Richard | Member Board | Profile | |
| Quiterie Beauregard | Head Portfolio | Profile | |
| Helen Martin | Head Management | Profile | |
| Julie Alimi | Head Legal | Profile | |
| Sebastien Enault | Chief Officer | Profile | |
| Christophe Douat | CEO Board | Profile | |
| Jaime Arango | CFO Board | Profile |
Other Information on Investing in MedinCell Pink Sheet
MedinCell financial ratios help investors to determine whether MedinCell Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in MedinCell with respect to the benefits of owning MedinCell security.